Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00034359 | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection | PHASE2 | COMPLETED | 79 | — | — | Feb 1, 2002 | Jan 1, 2003 | Feb 18, 2021 | 3 | Bulgaria, Federal Republic of Yugoslavia |
| Name | Type | Description |
|---|---|---|
| ACH-126,443 | DRUG | - |
| Lamivudine | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Chronic hepatitis B virus (HBV) infection, known to be hepatitis B surface antigen positive ≥ 6 months. * Plasma HBV deoxyribonucleic acid level ≥ 100,000 copies/milliliter. * Hepatitis B e-antigen positive. * Human immunodeficiency virus negative. * Basic hematologic and chem...